Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a significant decline, with a drop of over 5% and a previous plunge of more than 11% [1] Group 1: Stock Performance - As of the latest update, the stock is down 5%, trading at 95.1 HKD, with a trading volume of 82.17 million HKD [1] - The stock has seen a substantial decrease from its closing price of 113.2 HKD on January 13, reflecting a discount of approximately 17.98% on the new share placement price [1] Group 2: Share Placement Details - The company announced a placement of 2.1 million shares, which represents about 0.69% of the enlarged H shares and approximately 0.53% of the total issued shares [1] - The expected net proceeds from the placement are around 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds raised will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]
港股异动 | 药捷安康-B(02617)续跌超5% 昨日重挫逾11% 公司拟折让近18%配股筹资